These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 31565009)

  • 41. Moving towards a new era in the management of chronic immune thrombocytopenia.
    Wadenvik H; Olsson B
    Ann Hematol; 2010 Jul; 89 Suppl 1():87-93. PubMed ID: 20339846
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
    Grainger JD; Locatelli F; Chotsampancharoen T; Donyush E; Pongtanakul B; Komvilaisak P; Sosothikul D; Drelichman G; Sirachainan N; Holzhauer S; Lebedev V; Lemons R; Pospisilova D; Ramenghi U; Bussel JB; Bakshi KK; Iyengar M; Chan GW; Chagin KD; Theodore D; Marcello LM; Bailey CK
    Lancet; 2015 Oct; 386(10004):1649-58. PubMed ID: 26231455
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dental procedures in 24 patients with chronic immune thrombocytopenia in prospective clinical studies of eltrombopag.
    Tarantino MD; Fogarty PF; Shah P; Brainsky A
    Platelets; 2015; 26(1):93-6. PubMed ID: 24433306
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effectiveness and Safety of Avatrombopag in Liver Cancer Patients with Severe Thrombocytopenia: Real-World Data and Challenges.
    Huang A; Chen JF; Wu JZ; Gao Z; Shi YH; Fu XT; Zhang X; Liu WR; Gao Q; Sun HC; Shi GM; Fan J; Ding ZB; Zhou J
    J Oncol; 2022; 2022():9138195. PubMed ID: 36405248
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Diagnostic approach and treatment of immune thrombocytopenia in adults].
    Kolonić SO; Patekar MB; Milunović V
    Acta Med Croatica; 2013 Mar; 67(1):3-11. PubMed ID: 24279250
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and Incidence of Treatment-Related Adverse Events of Thrombopoietin Receptor Agonists in Adults with Immune Thrombocytopenia: A Systematic Review and Network Meta-Analysis of Randomized Controlled Study.
    Liu Y; Zhang HX; Su J; Geng QC; Lin X; Feng CX
    Acta Haematol; 2023; 146(3):173-184. PubMed ID: 36572014
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Use of Thrombopoietin Receptor Agonists in Childhood Immune Thrombocytopenia.
    Garzon AM; Mitchell WB
    Front Pediatr; 2015; 3():70. PubMed ID: 26322297
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Therapeutic options for adult patients with previously treated immune thrombocytopenia - a systematic review and network meta-analysis.
    Yang R; Lin L; Yao H; Ji O; Shen Q
    Hematology; 2019 Dec; 24(1):290-299. PubMed ID: 30661482
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical efficacy of avatrombopag and recombinant human thrombopoietin in the treatment of chronic liver disease-associated severe thrombocytopenia: A real-world study.
    Wang YS; Wang W; Zhang S; Zhang SY; Shen AZ; Wang W; Song HC; Yao HZ; Song RP; Meng FZ; Li L; Nashan B; Wang JZ; Liu LX
    Front Pharmacol; 2022; 13():1009612. PubMed ID: 36267268
    [No Abstract]   [Full Text] [Related]  

  • 50. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial.
    Bussel JB; Provan D; Shamsi T; Cheng G; Psaila B; Kovaleva L; Salama A; Jenkins JM; Roychowdhury D; Mayer B; Stone N; Arning M
    Lancet; 2009 Feb; 373(9664):641-8. PubMed ID: 19231632
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia.
    Afdhal NH; Giannini EG; Tayyab G; Mohsin A; Lee JW; Andriulli A; Jeffers L; McHutchison J; Chen PJ; Han KH; Campbell F; Hyde D; Brainsky A; Theodore D;
    N Engl J Med; 2012 Aug; 367(8):716-24. PubMed ID: 22913681
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Population Pharmacokinetic/Pharmacodynamic Analyses of Avatrombopag in Patients With Chronic Liver Disease and Optimal Dose Adjustment Guide With Concomitantly Administered CYP3A and CYP2C9 Inhibitors.
    Nomoto M; Ferry J; Hussein Z
    J Clin Pharmacol; 2018 Dec; 58(12):1629-1638. PubMed ID: 29905956
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Portal vein thrombosis during eltrombopag treatment for immune thrombocytopenic purpura in a patient with liver cirrhosis due to hepatitis C viral infection.
    Kawano N; Hasuike S; Iwakiri H; Nakamura K; Ozono Y; Kusumoto H; Nagata K; Kikuchi I; Yoshida S; Kuriyama T; Yamashita K; Muranaka T; Kawaguchi T; Sata M; Okamura T; Ueda A; Shimoda K
    J Clin Exp Hematop; 2013; 53(2):151-5. PubMed ID: 23995112
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Eltrombopag--an oral thrombopoietin agonist.
    Sharma V; Randhawa H; Sharma A; Aggarwal S
    Eur Rev Med Pharmacol Sci; 2012 Jun; 16(6):743-6. PubMed ID: 22913204
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia.
    Al-Samkari H; Kuter DJ
    Br J Haematol; 2018 Oct; 183(2):168. PubMed ID: 29978577
    [No Abstract]   [Full Text] [Related]  

  • 56. Pharmacokinetics, Pharmacodynamics, Pharmacogenomics, Safety, and Tolerability of Avatrombopag in Healthy Japanese and White Subjects.
    Nomoto M; Pastino G; Rege B; Aluri J; Ferry J; Han D
    Clin Pharmacol Drug Dev; 2018 Feb; 7(2):188-195. PubMed ID: 28339166
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Review article: a treatment algorithm for patients with chronic liver disease and severe thrombocytopenia undergoing elective medical procedures in the United States.
    Dieterich DT; Bernstein D; Flamm S; Pockros PJ; Reau N
    Aliment Pharmacol Ther; 2020 Oct; 52(8):1311-1322. PubMed ID: 32813292
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Thrombopoietin receptor agonists and risk of portal vein thrombosis in patients with liver disease and thrombocytopenia: A meta-analysis.
    Loffredo L; Violi F
    Dig Liver Dis; 2019 Jan; 51(1):24-27. PubMed ID: 29958825
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Eltrombopag as steroid sparing therapy for immune thrombocytopenic purpura in systemic lupus erythematosus.
    Maroun MC; Ososki R; Andersen JC; Dhar JP
    Lupus; 2015 Jun; 24(7):746-50. PubMed ID: 25416695
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Thrombopoietin Receptor Agonists: Can These Be the Future Answer to the Deadly Thrombocytopenia in Dengue Fever?
    Roy S
    Cureus; 2019 Apr; 11(4):e4361. PubMed ID: 31192066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.